Home › Stomach Cancer › Massachusetts
Stomach Cancer clinical trials in Massachusetts
34 studies for Stomach Cancer are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07059884A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06760819A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Oct 1, 2026 · NCT06586957Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Dana Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07700979A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07578571IKS014 in Advanced Solid Tumors That Express HER2
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05872295Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07114601A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213791Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
- Massachusetts General Hospital, Boston
- UMass/Shields, Worcester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07217704Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898Resilience and Equity in Aging, Cancer, and Health (REACH)
- Dana-Farber Cancer Institute, Boston
Recruiting
Ages 65 and older · All sexes · Updated Sep 10, 2026 · NCT04674267A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06253871Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Boston
- Research Site, Burlington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07431281A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07070232Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
- Massachusetts General Hospital, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07070466A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- Mass General Cancer Center, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT07227168A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Tufts Medical Center, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06731478A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital - Dana Farber, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 29, 2026 · NCT03526835A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT06131840A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- and 3 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT04389632Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Dana-Farber Cancer Institute, Boston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 30, 2026 · NCT07675967Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
- I-Mab Site 1002, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 14, 2026 · NCT07432295Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT06239194A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT06395519Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Mass General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 5, 2026 · NCT04900818CONFIRM: Magnetic Resonance Guided Radiation Therapy
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · All sexes · Updated Feb 9, 2026 · NCT04368702Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jan 16, 2026 · NCT02584244SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT05941507Comprehensive Outcomes for After Cancer Health
- Dana Farber Cancer Institute, Boston
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Dec 11, 2024 · NCT05349227From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.